Company Profiles

driven by the PitchBook Platform

Solasia Pharma

Description

Developer of innovative drugs specializing in oncology area created to improve quality of life for patients. The company's second candidate SP-02, or darinaparsin, is a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers, while its third product is a medical device to treat pain associated with oral mucositis, thus helping to minimize side effects caused by cancer treatment and support patients in a daily life.

2006

Founded

IPO REG.

Status

11-50

Employees

IPO

Latest Deal Type

$28.5M

Total Amount Raised

3

Investors

Description

Developer of innovative drugs specializing in oncology area created to improve quality of life for patients. The company's second candidate SP-02, or darinaparsin, is a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers, while its third product is a medical device to treat pain associated with oral mucositis, thus helping to minimize side effects caused by cancer treatment and support patients in a daily life.

Website:

www.solasia.co.jp

Formerly Known As

JapanBridge

Ownership Status

In IPO registration

Financing Status

Venture Capital-Backed

Primary Industry

Therapeutic Devices

Other Industries

Biotechnology
Drug Discovery

Primary Office

3F, Shiodome Building 1-2-20, Kaigan, Minato-ku Tokyo, 105-0022Japan +81 (0)36 721 8332
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Solasia Pharma's full profile, request a free trial.

Solasia Pharma Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Solasia Pharma Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Solasia Pharma Investors (3)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
ITOCHUCorporationMinority000 0000000 0000
Kyowa HakkoCorporationMinority000 0000000 0000
MPM CapitalVenture CapitalMinority000 0000000 0000
ITOCHU Corporation
Kyowa Hakko Corporation
MPM Capital Venture Capital

Solasia Pharma Executive Team (7)

NameTitleBoard
Seat
Contact
Info
Yoshihiro AraiChief Executive Officer, President & Board Member
Toshio MiyashitaChief Financial Officer, Board Member & Director
Vivian ZhangGeneral Manager
Koji ShinozakiHead of Business Development
Shigeru SakamakiHead, Product Development
Yoshihiro Arai Chief Executive Officer, President & Board Member
Toshio Miyashita Chief Financial Officer, Board Member & Director
Vivian Zhang General Manager
Koji Shinozaki Head of Business Development
Shigeru Sakamaki Head, Product Development

Solasia Pharma Board Members (11)

NameRepresentingRoleSinceContact
Info
Bard Geesaman Ph.DMPM CapitalManaging Director000 0000
Dave PrestonSelfBoard Member000 0000
James Scopa JDMPM CapitalManaging Director000 0000
Koji AbeITOCHUGeneral Manager, Innovative Tech. Business Development000 0000
Masahiro MichisujiSelfBoard Member000 0000
Bard Geesaman Ph.D Managing Director MPM Capital
Dave Preston Board Member Self
James Scopa JD Managing Director MPM Capital
Koji Abe General Manager, Innovative Tech. Business Development ITOCHU
Masahiro Michisuji Board Member Self
Request full access to PitchBook